Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > iCeutica and Nordic Biotech Sign an Agreement to Reformulate and Commercialise Nano-Compounds Using iCeutica’s EON™ Platform

Abstract:
-iCeutica Inc is pleased to announce that it has signed a binding agreement with Danish venture capital group Nordic Biotech to establish a new company Spree Pharma A/S. The agreement enables Spree to leverage iCeutica's proprietary Encapsulated Organic Nanoparticle (EON) Platform to reformulate a number of compounds for launch and marketing by Spree Pharma A/S in focused therapeutic indications.

iCeutica and Nordic Biotech Sign an Agreement to Reformulate and Commercialise Nano-Compounds Using iCeutica’s EON™ Platform

Philadelphia, PA | Posted on May 9th, 2007

The agreement provides for Nordic Biotech to invest in Spree Pharma A/S which will be co-owned by both iCeutica Inc and Nordic Biotech. Spree will be responsible for selection of drug compounds for reformulation using iCeutica's EON Platform and for their commercialisation. iCeutica will undertake the reformulation work under contract with Spree.

"We are happy to have started Spree Pharma A/S based on the iCeutica technology and look forward to building a therapeutically focused pharmaceutical company," said Nordic Biotech partner Florian Schönharting.

"This transaction combines iCeutica's EON Platform with the strong product development and management capabilities of Nordic," commented iCeutica CEO Matt Callahan. "This opportunity provides additional commercial opportunities for iCeutica with a highly credible player."

####

About iCeutica Inc.
iCeutica commercializes products developed by their proprietary EON™ Platform. EON is a validated enabling technology with the potential to provide low cost solutions to extending the clinically relevant life cycle of blockbuster drugs, as well as to become a cornerstone drug delivery technique for new chemical entities. The EON Platform provides a simple and scalable process to reformulate a range of different drugs.

About Nordic Biotech

Nordic Biotech Advisors was founded in 2001, and currently advises Nordic Biotech K/S and Nordic Biotech II K/S, with a combined committed capital of more than DKK 800 mill. Current portfolio companies include Curalogic A/S, Osteologix Inc., Forward Pharma A/S and Life Cycle Pharma A/S. Key Investors include Lundbeck Pharma, HBM Bioventures, Vækstfonden, Biotechnology Value Fund, LD Pensions, W Capital and the Lundbeck Foundation.

For more information, please click here

Contacts:
iCeutica Inc
by
Phoenix IP Ventures
Lisa Gray, Managing Partner
267-765-3233

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Harris & Harris Group Reports Financial Statements as of December 31, 2014 and Posts Annual Letter to Shareholders on Website March 17th, 2015

Arrowhead to Present at 2015 Barclays Global Healthcare Conference March 4th, 2015

Arrowhead to Present at 2015 RBC Capital Markets' Global Healthcare Conference February 17th, 2015

Iran 1st among Islamic Nations in Scientific Production, Nanotechnology February 16th, 2015

Nanomedicine

Novel nanoparticle therapy promotes wound healing March 27th, 2015

Graphene reduces wear of alumina ceramic March 26th, 2015

Application of Graphene Oxide in Body Implants in Iran March 26th, 2015

Nanotechnology in Medical Devices Market is expected to reach $8.5 Billion by 2019 March 25th, 2015

Announcements

UT Dallas engineers twist nanofibers to create structures tougher than bulletproof vests March 27th, 2015

Novel nanoparticle therapy promotes wound healing March 27th, 2015

Designer's toolkit for dynamic DNA nanomachines: Arm-waving nanorobot signals new flexibility in DNA origami March 27th, 2015

Using magnetic fields to understand high-temperature superconductivity: Los Alamos explores experimental path to potential 'next theory of superconductivity' March 27th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE